Sglt 2i CKD Farxiga denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for sglt2i ckd farxiga are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Farxiga for CKD as Not Medically Necessary — and How to Appeal

A medical-necessity denial means Cigna's reviewer concluded that the submitted documentation did not establish that dapagliflozin is required for your specific clinical situation, or that a less expensive alternative would be equally effective. This is the most common denial type for specialty-tier medications and it is routinely overturned — because the underlying clinical case is often sound, but the original authorization request lacked the structured documentation the plan needs to approve it.

For CKD patients, a medical-necessity denial often comes down to: missing or incomplete documentation of diagnosis and staging, absence of a prior-treatment history that demonstrates earlier therapies were tried and were insufficient, or a prescriber letter that states a conclusion without walking through the clinical reasoning. The appeal is an opportunity to rebuild that documentation comprehensively.

### Why This Denial Is Commonly Overturned

Independent external reviewers consistently overturn medical-necessity denials when the medical record, properly organized and submitted, shows that the prescribing decision aligns with FDA-approved use and the applicable clinical practice guidelines for CKD management. Your goal is to make it impossible for a clinical reviewer to identify an unanswered gap.

### Federal Appeal Framework

• Internal appeal (ACA / ERISA §503): File within the deadline on the denial letter — typically 180 days. You are entitled to a full-and-fair review by a clinical reviewer not involved in the prior denial.
• External review (ACA §2719): If the internal appeal fails, file for independent external review within approximately four months of the final internal denial. The external reviewer's decision is binding on Cigna.
• Expedited review: If your health would be seriously jeopardized by waiting, both internal and external reviews may be expedited — typically 72-hour turnaround.

### Concrete Appeal Steps and Timeline

1. Read the denial letter carefully. Cigna is required to state the specific clinical criteria not met — record each one. 2. Pull Cigna's published clinical coverage policy for SGLT2 inhibitors / dapagliflozin in CKD from Cigna's website. Print and annotate the medical-necessity criteria. 3. Pull the FDA-approved prescribing information for Farxiga. Confirm the CKD indication language. 4. Compile every chart record relevant to your CKD diagnosis, prior treatments, and clinical course. 5. Ask your prescribing physician and, if involved, your nephrologist to write a detailed medical-necessity letter. 6. Submit the internal appeal. If denied, file immediately for external review.

### Documentation to Gather

• Diagnosis confirmation: Nephrology or primary-care notes establishing CKD diagnosis, stage, and relevant clinical trajectory — with dates.
• Prior treatment history: Dated records for every medication previously used to slow CKD progression, with the reason each was stopped or was insufficient.
• Clinical severity documentation: Physician notes and any lab trend records showing disease course (your physician will cite the applicable values from recognized guidelines).
• Comorbidity records: Documentation of any cardiovascular or other conditions relevant to the prescribing decision.
• Prescriber medical-necessity letter: A signed, detailed letter that maps the patient's clinical profile to each criterion in Cigna's coverage policy and the FDA-approved indication.

### Criteria-Mapping Structure

Build your appeal letter as a direct response to each requirement in Cigna's coverage policy. Quote the criterion verbatim, then cite the specific chart document, date, and finding that satisfies it. Do not leave any criterion unanswered. A reviewer should be able to check off each requirement without searching for the supporting fact.